Add-on efgartigimod in myasthenic crisis: a promising treatment option
This suggests that efgartigimod may serve as an alternative option for MC patients or as a rescue treatment option for refractory individuals.
Authors
- Huiyu Feng
- Hongyan Zhou (ORCID: https://orcid.org/0000-0002-4210-3476)
- Cunzhou Shen
- J. Jean Chen
- Hao Wang (ORCID: https://orcid.org/0000-0001-6881-9977)
- Rong Lai
- Xunsha null Sun
- Jing Wang
- Fangyi Shi
- Xin Huang
- Jiezhen Feng
- Li Feng
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.3389/fneur.2025.1696976
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 39.15
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province